pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2607Research ArticleЛЕКЦИИLECTIONSМоксифлоксацин улучшает долговременный прогноз у больных с инфекционным обострением хронического бронхитаMoxifloxacin improves long-term prognosis in patients with infectious-dependent exacerbation of chronic bronchitisДворецкийЛ. И.DvoretskyL. I.
Москва
ЯковлевС. В.YakovkevS. V.
Москва
НониковВ. Е.NonikovV. E.
Москва
СтрекачевА. Ю.StrekachevA. Yu.
Москва
ДубровскаяН. В.DubrovskayaN. V.
Москва
ММА им. И.М.Сеченова;
ЦКБ УД Президента РФRussian Federation20030209202106121124Copyright © Дворецкий Л.И., Яковлев С.В., Ноников В.Е., Стрекачев А.Ю., Дубровская Н.В., 20212021Дворецкий Л.И., Яковлев С.В., Ноников В.Е., Стрекачев А.Ю., Дубровская Н.В.Dvoretsky L.I., Yakovkev S.V., Nonikov V.E., Strekachev A.Y., Dubrovskaya N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2607
.
ReferencesAnthoniseti N.R., Manfreda J., Warren С.P. et al. Antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.Anthoniseti N.R., Manfreda J., Warren С.P. et al. Antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.Bauer Т., Landen H. Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis. Comparison with prior macrolide therapy. Clin. Drug Invest. 2002; 22 (10): 641-651.Bauer Т., Landen H. Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis. Comparison with prior macrolide therapy. Clin. Drug Invest. 2002; 22 (10): 641-651.Chodosh S., Schreurs A., Siamai G. et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin. Infect. Dis. 1998; 27: 730-738.Chodosh S., Schreurs A., Siamai G. et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin. Infect. Dis. 1998; 27: 730-738.DeAbate C.A., Mathew C.P., Warner J.H. et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir. Med. 2000; 94: 1029-1037.DeAbate C.A., Mathew C.P., Warner J.H. et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir. Med. 2000; 94: 1029-1037.Hoban D., Felmingham D. The PROTECT surveillance study: antimicrobial susceptibility of H.influenzae and M.catarrhalis from community-acquired respiratory tract infections. J. Antimicrob. Chemother. 2002; 50 (suppl. 1): 49-59.Hoban D., Felmingham D. The PROTECT surveillance study: antimicrobial susceptibility of H.influenzae and M.catarrhalis from community-acquired respiratory tract infections. J. Antimicrob. Chemother. 2002; 50 (suppl. 1): 49-59.Moxon E.R., Murphy T.F. Haemophilus influenzae. In: Mandell G.L., Bennett J.E., Dolin R., eds. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2000; vol.2: 2369-2378.Moxon E.R., Murphy T.F. Haemophilus influenzae. In: Mandell G.L., Bennett J.E., Dolin R., eds. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone; 2000; vol.2: 2369-2378.Murhy T.F., Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1992; 146: 1067-1083.Murhy T.F., Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1992; 146: 1067-1083.Pechere J.-C., Lacey L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbation of chronic bronchitis. J. Antimicrob. Chemother. 2000; 45 (topic T2): 19-24.Pechere J.-C., Lacey L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbation of chronic bronchitis. J. Antimicrob. Chemother. 2000; 45 (topic T2): 19-24.Saint S., Bent S., Vittinghoff E. et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. J.A.M.A. 1995; 273: 957-960.Saint S., Bent S., Vittinghoff E. et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. J.A.M.A. 1995; 273: 957-960.Saravolatz L.D ., Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin. Infect. Dis. 2003; 37: 1210-1215.Saravolatz L.D ., Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin. Infect. Dis. 2003; 37: 1210-1215.Tran J.Q., Ballow C.H., Forrest A. et al. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. J. Antimicrob. Chemother. 2000; 45 (topic T2): 9-17.Tran J.Q., Ballow C.H., Forrest A. et al. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. J. Antimicrob. Chemother. 2000; 45 (topic T2): 9-17.Wilson R., Jones P., Schaberg T. et al. A clinical and outcomes assessment of the management of acute exacerbation of chronic bronchitis (AECB): the M O SAIC study. Eur. Respir. J. 2003; 22 (suppl.45): abstr. P3371.Wilson R., Jones P., Schaberg T. et al. A clinical and outcomes assessment of the management of acute exacerbation of chronic bronchitis (AECB): the M O SAIC study. Eur. Respir. J. 2003; 22 (suppl.45): abstr. P3371.Wilson R., Allegra L., Huchon G. et al. The MOSAIC study: prognostic subgroup analysis of the efficacy of moxifloxacin (M FX ) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (A EC B). In: 43rd ICAAC. Chicago; 2003. abstr. L-1593.Wilson R., Allegra L., Huchon G. et al. The MOSAIC study: prognostic subgroup analysis of the efficacy of moxifloxacin (M FX ) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (A EC B). In: 43rd ICAAC. Chicago; 2003. abstr. L-1593.
The authors declare that there are no conflicts of interest present.